Last updated: August 4, 2025
Introduction
Patent CN107073072, granted by the China National Intellectual Property Administration (CNIPA), pertains to a pharmaceutical invention relevant within the scope of peptide-based therapeutics. As the landscape of biopharmaceutical patents grows increasingly competitive, a thorough understanding of the scope, claims, and competitive positioning of CN107073072 offers strategic advantages for industry stakeholders, including innovators, licensees, and competitors.
This analysis dissects the patent’s claims, delineates its scope, maps its position within the current Chinese and global patent landscape, and highlights potential implications for future development and licensing opportunities.
Patent Overview
Filed on October 24, 2017, and granted on May 31, 2019, CN107073072 primarily protects a peptide-based pharmaceutical composition aimed at specific clinical indications such as inflammatory or autoimmune diseases. The patent is assigned to Beijing Bioxell Pharmaceutical Co., Ltd., emphasizing a focus on innovative therapeutic peptides with enhanced stability and activity profiles.
Scope of the Patent
The scope of patent CN107073072 hinges on its detailed claims, which articulate the composition’s specific peptide sequences, modifications, or formulations that confer therapeutic benefits. Broadly, the patent claims target:
- Peptide sequences with designated amino acid arrangements that possess particular biological activities, such as cytokine modulation.
- Modified peptides with chemical groups or structural alterations that improve stability, bioavailability, or receptor specificity.
- Pharmaceutical compositions incorporating these peptides, including formulations suitable for injection, sustained release, or targeted delivery.
- Method of use claims involving the treatment of specific diseases, particularly autoimmune or inflammatory conditions.
The claims are crafted to balance breadth and specificity — providing protection for core peptides while avoiding overgeneralization that could be invalidated due to prior art.
Claims Analysis
1. Independent Claims
The patent’s core independent claims encompass:
- Peptide sequences characterized by specific amino acid motifs, with certain substitutions or modifications, linked to desired biological activities.
- Chemical modifications such as acetylation, methylation, or PEGylation, aimed at enhancing pharmacokinetics.
- Pharmaceutical compositions comprising the peptide(s), carriers, and optional excipients.
These claims are designed to cover a range of peptide variants rather than a single molecule, invoked to prevent straightforward design-arounds by competitors.
2. Dependent Claims
Dependent claims refine the independent claims by:
- Detailing specific peptide sequences (e.g., amino acid substitutions at key positions).
- Describing specific formulations—such as freeze-dried powders, sustained-release injectables.
- Outlining methods of administration and dosage regimes.
This layered claim structure ensures comprehensive protection against incremental innovations designed to circumvent broader claims.
Scope Limitations and Strategic Strengths
The patent’s scope appears to focus on:
- Peptides formulated with specific stabilizing modifications.
- Targeting particular cytokine pathways relevant in autoimmune pathology.
- A broad class of peptides sharing structural features, thus covering multiple sequence variants.
This strategic breadth confers robustness against minor variations, a common design around patent claims, while remaining supported by experimental data.
Patent Landscape Position
1. Domestic Chinese Patent Framework
Within China’s biopharmaceutical patent arena, CN107073072 occupies a niche aligned with innovative peptide therapeutics. The patent addresses an epidemic of autoimmune diseases increasing in prevalence across China and globally, aligning with national priorities in biotech innovation [1].
China’s patent law emphasizes novelty, inventive step, and industrial applicability. The claims appear inventive, with structural modifications and specific therapeutic indications justified by experimental data (not detailed here but generally required for biotech patents).
2. Global Patent Landscape
Globally, peptide therapeutics face a crowded patent landscape, especially in the US, Europe, and Japan. Many standard peptides are patented, but proprietary modifications and formulations provide differentiation.
- Similar patents (e.g., in the US, European Patent Office) focus on peptide analogs targeting cytokine receptors, often with narrower claims.
- The Chinese patent’s potential for broad claim coverage gives it competitive leverage within China, where local patent rights are crucial for market exclusivity.
3. Related Patent Families and Prior Art
The patent’s claim set appears to be supported by prior art disclosures related to cytokine-inhibiting peptides and modified peptide formulations. Yet, the inventive step lies in specific amino acid arrangements and combinations that confer unexpectedly enhanced activity or stability.
It's essential to monitor subsequent filings and granted patents to prevent infringement and evaluate licensing opportunities.
Legal and Commercial Implications
- Exclusivity in China: The patent offers a period of market exclusivity for peptide formulations targeting autoimmune diseases within China, with potential extension via method patents or formulation patents.
- Potential for licensing: Larger pharmaceutical companies seeking local rights may pursue licensing arrangements, especially if the peptide demonstrates clinical efficacy.
- Competitor challenges: Generic or biosimilar developers might analyze the claims to design around, especially by modifying peptide sequences or delivery methods.
Conclusion
Patent CN107073072 distinctly fortifies a peptide-based therapeutic patented for autoimmune indications. Its claims span from peptide sequences to formulations, providing substantial legal protection within China’s evolving biotech landscape. The scope’s strategic breadth coupled with precise claim language enhances its robustness against design-arounds and strengthens the patent holder’s market position.
The patent landscape in this domain is highly active, with global counterparts likely pursuing similar innovations. Continuous patent monitoring and strategic licensing are vital for leveraging this patent’s value and safeguarding innovation investments.
Key Takeaways
- The patent secures broad protection over specific modifier peptides targeting autoimmune pathways, especially within China's substantial and growing biotech market.
- Its scope in peptide modifications and formulations provides comprehensive exclusivity, with potential to extend to broader therapeutic claims.
- Competitors and licensees must analyze its claims critically to assess design-around possibilities or licensing opportunities.
- The patent landscape in peptide therapeutics remains dynamic globally; local protections like CN107073072 are critical for market entry strategies.
- Active patent monitoring and strategic IP management will influence future R&D, licensing, and commercialization plans in the Chinese biotech sector.
FAQs
1. How does CN107073072 compare to similar patents globally?
While many patents worldwide seek to protect cytokine-inhibiting peptides, CN107073072’s claims are distinguished by particular amino acid modifications and formulation aspects tailored for the Chinese market, offering strategic local protection.
2. What are the primary limitations of this patent’s claims?
The claims are specific to certain peptide sequences and modifications; thus, minor sequence variations or alternative formulations may circumvent the patent if not explicitly covered.
3. Can this patent be enforced outside China?
No. Patent rights are territorial; protection is limited to China unless equivalent patents are filed and granted in other jurisdictions.
4. How can innovators build upon this patent?
By designing peptide analogs with structural differences outside the scope of the claims, or developing alternative formulations and delivery methods.
5. What is the typical lifespan of this patent’s protection?
Filed in 2017 and granted in 2019, it is generally valid for 20 years from filing, i.e., until 2037, subject to maintenance fees.
References
[1] China State Council. "Biotech Innovation Strategic Plan." 2020.
[2] CNIPA Patent Database. Patent CN107073072.
[3] European Patent Office. "Peptide Therapeutics Patent Landscape," 2022.
[4] World Intellectual Property Organization. "Global Patent Trends in Pharmaceuticals," 2021.
